Clinical Trial
doi: 10.3109/00365528708991953.
Olsalazine in patients intolerant of sulphasalazine
Affiliations
- PMID: 2892247
- DOI: 10.3109/00365528708991953
Item in Clipboard
Clinical Trial
Olsalazine in patients intolerant of sulphasalazine
Scand J Gastroenterol.
1987 Nov.
Abstract
Fifty patients with ulcerative colitis, intolerant of sulphasalazine, were treated with 500 mg olsalazine twice daily for a 3-month trial period. Thirty-eight of the patients (76%) tolerated the drug well, and all continued to take it beyond the 3-month period. Twelve (24%) were withdrawn because of side effects, the commonest being diarrhoea. There were no haematologic or biochemical abnormalities. Thus, olsalazine is a useful drug for patients who are intolerant of sulphasalazine.
Similar articles
-
Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.Scand J Gastroenterol. 1987 Apr;22(3):332-6. doi: 10.3109/00365528709078600. Scand J Gastroenterol. 1987. PMID: 2884724 Clinical Trial.
-
Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.Scand J Gastroenterol Suppl. 1988;148:70-5. doi: 10.3109/00365528809101553. Scand J Gastroenterol Suppl. 1988. PMID: 2906479 Clinical Trial.
-
Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.Scand J Gastroenterol Suppl. 1988;148:45-7. doi: 10.3109/00365528809101547. Scand J Gastroenterol Suppl. 1988. PMID: 2906477 Clinical Trial.
-
The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.Rev Gastroenterol Disord. 2004 Spring;4(2):86-91. Rev Gastroenterol Disord. 2004. PMID: 15185719 Review.
-
Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.Clin Pharm. 1992 Jun;11(6):514-28. Clin Pharm. 1992. PMID: 1600685 Review.
Cited by
-
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev. 2020 Aug 28;8(8):CD000544. doi: 10.1002/14651858.CD000544.pub5. Cochrane Database Syst Rev. 2020. PMID: 32856298 Free PMC article.
-
Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.Gut. 1992 Feb;33(2):252-5. doi: 10.1136/gut.33.2.252. Gut. 1992. PMID: 1347280 Free PMC article. Clinical Trial.
-
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD000543. doi: 10.1002/14651858.CD000543.pub4. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Aug 12;8:CD000543. doi: 10.1002/14651858.CD000543.pub5. PMID: 27101467 Free PMC article. Updated.
-
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Cochrane Database Syst Rev. 2020 Aug 12;8(8):CD000543. doi: 10.1002/14651858.CD000543.pub5. Cochrane Database Syst Rev. 2020. PMID: 32786164 Free PMC article.
-
Drug therapy of ulcerative colitis.Br J Clin Pharmacol. 1992 Sep;34(3):189-98. doi: 10.1111/j.1365-2125.1992.tb04124.x. Br J Clin Pharmacol. 1992. PMID: 1389944 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
